Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.
Identifieur interne : 000579 ( Ncbi/Merge ); précédent : 000578; suivant : 000580Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.
Auteurs : Elena Armandola [Allemagne]Source :
- MedGenMed : Medscape general medicine [ 1531-0132 ] ; 2003.
Descripteurs français
- KwdFr :
- ADN viral (usage thérapeutique), Animaux, Complexes immunostimulants (usage thérapeutique), Ebolavirus (immunologie), Ebolavirus (pathogénicité), Espagne, Fièvre hémorragique à virus Ebola (), Humains, Immunité cellulaire (physiologie), Immunité muqueuse (physiologie), Infections à VIH (), Lymphocytes T cytotoxiques (physiologie), Produits du gène env (usage thérapeutique), Produits du gène gag (usage thérapeutique), Produits du gène tat du virus de l'immunodéficience humaine, Protéines du gène tat (usage thérapeutique), Syndrome d'immunodéficience acquise (), Syndrome respiratoire aigu sévère (), VIH (Virus de l'Immunodéficience Humaine) (immunologie), VIH (Virus de l'Immunodéficience Humaine) (pathogénicité), Vaccins contre la maladie à virus Ebola (usage thérapeutique), Vaccins contre le SIDA (usage thérapeutique), Vaccins à ADN (usage thérapeutique), Virus du SRAS (immunologie), Virus du SRAS (pathogénicité).
- MESH :
- immunologie : Ebolavirus, VIH (Virus de l'Immunodéficience Humaine), Virus du SRAS.
- pathogénicité : Ebolavirus, VIH (Virus de l'Immunodéficience Humaine), Virus du SRAS.
- physiologie : Immunité cellulaire, Immunité muqueuse, Lymphocytes T cytotoxiques.
- usage thérapeutique : ADN viral, Complexes immunostimulants, Produits du gène env, Produits du gène gag, Protéines du gène tat, Vaccins contre la maladie à virus Ebola, Vaccins contre le SIDA, Vaccins à ADN.
- Animaux, Espagne, Fièvre hémorragique à virus Ebola, Humains, Infections à VIH, Produits du gène tat du virus de l'immunodéficience humaine, Syndrome d'immunodéficience acquise, Syndrome respiratoire aigu sévère.
English descriptors
- KwdEn :
- AIDS Vaccines (therapeutic use), Acquired Immunodeficiency Syndrome (prevention & control), Animals, DNA, Viral (therapeutic use), Ebola Vaccines (therapeutic use), Ebolavirus (immunology), Ebolavirus (pathogenicity), Gene Products, env (therapeutic use), Gene Products, gag (therapeutic use), Gene Products, tat (therapeutic use), HIV (immunology), HIV (pathogenicity), HIV Infections (prevention & control), Hemorrhagic Fever, Ebola (prevention & control), Humans, ISCOMs (therapeutic use), Immunity, Cellular (physiology), Immunity, Mucosal (physiology), SARS Virus (immunology), SARS Virus (pathogenicity), Severe Acute Respiratory Syndrome (prevention & control), Spain, T-Lymphocytes, Cytotoxic (physiology), Vaccines, DNA (therapeutic use), tat Gene Products, Human Immunodeficiency Virus.
- MESH :
- chemical , therapeutic use : AIDS Vaccines, DNA, Viral, Ebola Vaccines, Gene Products, env, Gene Products, gag, Gene Products, tat, ISCOMs, Vaccines, DNA.
- immunology : Ebolavirus, HIV, SARS Virus.
- pathogenicity : Ebolavirus, HIV, SARS Virus.
- physiology : Immunity, Cellular, Immunity, Mucosal, T-Lymphocytes, Cytotoxic.
- prevention & control : Acquired Immunodeficiency Syndrome, HIV Infections, Hemorrhagic Fever, Ebola, Severe Acute Respiratory Syndrome.
- Animals, Humans, Spain, tat Gene Products, Human Immunodeficiency Virus.
PubMed: 14745371
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002F76
- to stream PubMed, to step Curation: 002F76
- to stream PubMed, to step Checkpoint: 003292
Links to Exploration step
pubmed:14745371Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.</title><author><name sortKey="Armandola, Elena" sort="Armandola, Elena" uniqKey="Armandola E" first="Elena" last="Armandola">Elena Armandola</name><affiliation wicri:level="3"><nlm:affiliation>European Patent Office, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>European Patent Office, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14745371</idno><idno type="pmid">14745371</idno><idno type="wicri:Area/PubMed/Corpus">002F76</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002F76</idno><idno type="wicri:Area/PubMed/Curation">002F76</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002F76</idno><idno type="wicri:Area/PubMed/Checkpoint">003292</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003292</idno><idno type="wicri:Area/Ncbi/Merge">000579</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.</title><author><name sortKey="Armandola, Elena" sort="Armandola, Elena" uniqKey="Armandola E" first="Elena" last="Armandola">Elena Armandola</name><affiliation wicri:level="3"><nlm:affiliation>European Patent Office, Munich, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>European Patent Office, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></analytic><series><title level="j">MedGenMed : Medscape general medicine</title><idno type="eISSN">1531-0132</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS Vaccines (therapeutic use)</term><term>Acquired Immunodeficiency Syndrome (prevention & control)</term><term>Animals</term><term>DNA, Viral (therapeutic use)</term><term>Ebola Vaccines (therapeutic use)</term><term>Ebolavirus (immunology)</term><term>Ebolavirus (pathogenicity)</term><term>Gene Products, env (therapeutic use)</term><term>Gene Products, gag (therapeutic use)</term><term>Gene Products, tat (therapeutic use)</term><term>HIV (immunology)</term><term>HIV (pathogenicity)</term><term>HIV Infections (prevention & control)</term><term>Hemorrhagic Fever, Ebola (prevention & control)</term><term>Humans</term><term>ISCOMs (therapeutic use)</term><term>Immunity, Cellular (physiology)</term><term>Immunity, Mucosal (physiology)</term><term>SARS Virus (immunology)</term><term>SARS Virus (pathogenicity)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spain</term><term>T-Lymphocytes, Cytotoxic (physiology)</term><term>Vaccines, DNA (therapeutic use)</term><term>tat Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (usage thérapeutique)</term><term>Animaux</term><term>Complexes immunostimulants (usage thérapeutique)</term><term>Ebolavirus (immunologie)</term><term>Ebolavirus (pathogénicité)</term><term>Espagne</term><term>Fièvre hémorragique à virus Ebola ()</term><term>Humains</term><term>Immunité cellulaire (physiologie)</term><term>Immunité muqueuse (physiologie)</term><term>Infections à VIH ()</term><term>Lymphocytes T cytotoxiques (physiologie)</term><term>Produits du gène env (usage thérapeutique)</term><term>Produits du gène gag (usage thérapeutique)</term><term>Produits du gène tat du virus de l'immunodéficience humaine</term><term>Protéines du gène tat (usage thérapeutique)</term><term>Syndrome d'immunodéficience acquise ()</term><term>Syndrome respiratoire aigu sévère ()</term><term>VIH (Virus de l'Immunodéficience Humaine) (immunologie)</term><term>VIH (Virus de l'Immunodéficience Humaine) (pathogénicité)</term><term>Vaccins contre la maladie à virus Ebola (usage thérapeutique)</term><term>Vaccins contre le SIDA (usage thérapeutique)</term><term>Vaccins à ADN (usage thérapeutique)</term><term>Virus du SRAS (immunologie)</term><term>Virus du SRAS (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>AIDS Vaccines</term><term>DNA, Viral</term><term>Ebola Vaccines</term><term>Gene Products, env</term><term>Gene Products, gag</term><term>Gene Products, tat</term><term>ISCOMs</term><term>Vaccines, DNA</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Ebolavirus</term><term>VIH (Virus de l'Immunodéficience Humaine)</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Ebolavirus</term><term>HIV</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Ebolavirus</term><term>HIV</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Ebolavirus</term><term>VIH (Virus de l'Immunodéficience Humaine)</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Immunité cellulaire</term><term>Immunité muqueuse</term><term>Lymphocytes T cytotoxiques</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Immunity, Cellular</term><term>Immunity, Mucosal</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term><term>Hemorrhagic Fever, Ebola</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>ADN viral</term><term>Complexes immunostimulants</term><term>Produits du gène env</term><term>Produits du gène gag</term><term>Protéines du gène tat</term><term>Vaccins contre la maladie à virus Ebola</term><term>Vaccins contre le SIDA</term><term>Vaccins à ADN</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Spain</term><term>tat Gene Products, Human Immunodeficiency Virus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Espagne</term><term>Fièvre hémorragique à virus Ebola</term><term>Humains</term><term>Infections à VIH</term><term>Produits du gène tat du virus de l'immunodéficience humaine</term><term>Syndrome d'immunodéficience acquise</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14745371</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1531-0132</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>MedGenMed : Medscape general medicine</Title><ISOAbbreviation>MedGenMed</ISOAbbreviation></Journal><ArticleTitle>Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.</ArticleTitle><Pagination><MedlinePgn>24</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Armandola</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>European Patent Office, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016423">Congress</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2003</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MedGenMed</MedlineTA><NlmUniqueID>100894134</NlmUniqueID><ISSNLinking>1531-0132</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016915">AIDS Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046129">Ebola Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015686">Gene Products, env</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015683">Gene Products, gag</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015696">Gene Products, tat</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016882">ISCOMs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054322">tat Gene Products, Human Immunodeficiency Virus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D016915" MajorTopicYN="N">AIDS Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000163" MajorTopicYN="N">Acquired Immunodeficiency Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D046129" MajorTopicYN="N">Ebola Vaccines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029043" MajorTopicYN="N">Ebolavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015686" MajorTopicYN="N">Gene Products, env</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015683" MajorTopicYN="N">Gene Products, gag</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015696" MajorTopicYN="N">Gene Products, tat</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019142" MajorTopicYN="N">Hemorrhagic Fever, Ebola</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016882" MajorTopicYN="N">ISCOMs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="N">Immunity, Mucosal</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054322" MajorTopicYN="N">tat Gene Products, Human Immunodeficiency Virus</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>1</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>1</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14745371</ArticleId><ArticleId IdType="pii">464592</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Armandola, Elena" sort="Armandola, Elena" uniqKey="Armandola E" first="Elena" last="Armandola">Elena Armandola</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000579 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000579 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:14745371
|texte= Conference report - I. Investigating new vaccines: Ebola and HIV: highlights from the Viral Vaccine Meeting; October 25-28, 2003; Barcelona, Spain.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:14745371" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |